Who Are the Core Customers of Thermo Fisher Scientific Company?

Pharmaceutical companies and biotech firms drive roughly 50 percent of Thermo Fisher Scientific customers and revenue in 2025, ranging from Big Pharma to small biotech startups that buy instruments, reagents, and contract development and manufacturing services (CDMO) for drug discovery, development, and production.

Academic and government research institutions, plus industrial and applied science laboratories (environmental, agricultural, materials), form large secondary customer segments-purchasing genomics and proteomics equipment, consumables, and lab services for basic and applied research.

Thermo Fisher serves businesses and institutions (B2B and B2B2C) rather than individual consumers; core customers include contract research organizations, clinical trial sponsors, hospital laboratories, and government agencies that buy instruments, software, and services.

The Pharma and Biotech segment is the most commercially important in 2025/2026, supporting end-to-end needs-discovery through manufacturing-and boosted by the PPD integration that expanded Clinical Research capabilities and CDMO scale; for more on customer choice see Why Customers Choose Thermo Fisher Scientific Company.

North America and Europe remain the core markets for Thermo Fisher Scientific customers, reflecting mature pharmaceutical companies, large research laboratories, and hospital laboratories that buy Thermo Fisher instruments and consumables; these regions account for more than 75% of fiscal 2025 revenue.

Asia – Pacific is the fastest expanding regional market, driven by bioprocessing hubs and contract manufacturing growth in China, South Korea, and Singapore; academic research labs and biotech startups in India and Southeast Asia also increase purchases of Thermo Fisher Scientific products.

Demand concentrates in Life Sciences Solutions and Analytical Instruments segments, serving proteomics and genomics labs, contract research organizations, and pharmaceutical companies; these segments drove a majority of segment revenue in fiscal 2025, supported by scale in reagents, instruments, and services.

Proteomics demand surged after the Olink integration as clinical researchers and genomics and proteomics labs seek high – multiplex protein assays for biomarker discovery; CDMO services remain resilient as biotech companies outsource manufacturing-Thermo Fisher's biomanufacturing bookings grew in 2025 amid rising contract volumes.

Thermo Fisher enters adjacent niches-advanced proteomics, clinical trial management, specialty diagnostics-via a disciplined string-of-pearls acquisition strategy that buys leaders in high-growth pockets and folds them into its sales and service network. This brings new Thermo Fisher Scientific customers from clinical trial sponsors and contract research organizations while keeping the research laboratories and biotech companies pipeline intact.

Thermo Fisher core customers-academic research labs, pharmaceutical companies, hospital laboratories-remain central because the company maintains focus on high-spec instruments and trusted technical support. The PPI (Practical Process Improvement) Business System standardizes integration, protecting quality and brand identity as new client segments adopt products.

Recurring revenue comes from standardized, high-volume consumables and service contracts that create ecosystem stickiness; Thermo Fisher reports consumables and services accounted for roughly ~56% of revenue in 2025, driving repeat purchases from biotech startups, industrial laboratories, and environmental testing labs. Renewals and multi-year service agreements reduce churn among Thermo Fisher customers in pharmaceutical industry and clinical diagnostic laboratories customers of Thermo Fisher.

The strongest growth lever is strategic M&A plus cross-sell: acquiring niche leaders and selling them into Thermo Fisher's existing global sales footprint lifted product attach rates and drove margin expansion. In 2025 the company invested to expand genomics and proteomics labs customer base and reported consolidated operating margin improvement year-over-year, highlighting that positioning as strategic partner wins larger accounts among pharmaceutical companies and government research agencies using Thermo Fisher.